NCT07707063 This a Clinical Trial to Evaluate the Efficacy of I-PRF, Povidone-Iodine and Laser as Adjuncts to Non-surgical Periodontal Treatment in Smokers and Non-Smokers Periodontitis Patients
| NCT ID | NCT07707063 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Military Hospital of Tunis |
| Condition | Periodontitis |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2026-05-25 |
| Primary Completion | 2027-05-18 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 50 participants in total. It began in 2026-05-25 with a primary completion date of 2027-05-18.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a randomized, controlled, split-mouth clinical trial designed to evaluate and compare the effectiveness of four different subgingival adjuncts used along side standard Scaling and Root Planning (SRP). This protocol is designed to be a standardized therapeutic model. The subgingival adjuncts are standardized, ensuring that the results are not operator dependent and can be replicated across any dental unit. The primary goal of this study is to evaluate the clinical efficacy of three distinct adjunctive strategies: Biological (I-PRF), Antiseptic : Povidone- iodine , Diode-Laser activation, compared to a Saline Control in the initial treatment of stage 2, 3 and stage 4 of the 2018 AAP/EFP periodontal classification.
Eligibility Criteria
Inclusion: Patients with Stage II-IV Periodontitis; at least one bleeding pocket \> 4 mm minimum in every quadrant. Exclusion: patients who: * Pregnant /Lactating * History of radiotherapy or chemotherapy in the head/neck region. * Known hypersensitivity to Iodine or Methylene blue solution * Systematic antibiotic use within the last 30 days * Long-term use of immunosuppressants or corticosteroids (daily use) * type 1 / 2 diabetes
Contact & Investigator
Hela Jegham, DDS -Professor
STUDY DIRECTOR
Military Hospital of Instruction of Tunis
Frequently Asked Questions
Who can join the NCT07707063 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Periodontitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07707063 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07707063 currently recruiting?
Yes, NCT07707063 is actively recruiting participants. Contact the research team at hela.jegham@yahoo.fr for enrollment information.
Where is the NCT07707063 trial being conducted?
This trial is being conducted at Tunis, Tunisia.
Who is sponsoring the NCT07707063 clinical trial?
NCT07707063 is sponsored by Military Hospital of Tunis. The principal investigator is Hela Jegham, DDS -Professor at Military Hospital of Instruction of Tunis. The trial plans to enroll 50 participants.